TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05296954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high resolution cartography
Description: High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high resolution cartography
Description: High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.
Study: NCT06390774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-705
Description: anti-PD-1 and anti-HER2 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-705
Description: anti-PD-1 and anti-HER2 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-705
Description: anti-PD-1 and anti-HER2 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-705
Description: anti-PD-1 and anti-HER2 bispecific antibody
Study: NCT04733937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a2 Platinum® stage 1 infant formula
Description: Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, A1 and A2 β-casein containing stage 1 infant formula
Description: Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
Study: NCT06193603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True dry cupping therapy
Description: In the intervention group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. The therapist will perform 5 minutes of dry cupping therapy, moving the cups up and down using both hands. Participants will also receive routine physiotherapy, including a 20-minute session of transcutaneous electrical stimulation with a frequency of 100 pulses per second and a duration of 60 microseconds. The stimulation intensity will be adjusted for sensory stimulus. Stabilization exercises like abdominal hollowing and bridging will be included. The treatment will consist of 10 sessions, three times per week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham cupping therapy
Description: In the control group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. However, unlike the intervention group, the cups in the control group will not be moved and will remain stationary for 5 minutes. The cups will have small holes (\<2mm in diameter) to release negative pressure quickly. Double-sided tapes will be used to secure the cups and maintain contact with the skin.
Study: NCT05564026

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Questionnaire provide to participant's about their health and quality of life since treatment

Intervention type: OTHER
Intervention: Tumor Specimen Collection
Description: Tumor DNA requested from the Biopathology Center

Intervention type: OTHER
Intervention: Germline DNA Samples
Description: Germline DNA specimens requested from the Biopathology Center or newly collected saliva

Intervention type: PROCEDURE
Intervention: Blood Sample Collection
Description: Collection and storing of serum/plasma
Study: NCT06563544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FCV
Description: 90 minutes of FCV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FCV
Description: 90 minutes of FCV
Study: NCT05811585

Intervention type: DEVICE
Intervention: ADEPT
Description: Adhesion Reduction Solution (4% icodextrin solution)
Study: NCT05775003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise training program - consisting of weight training and cardiovascular exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise training program - consisting of weight training and cardiovascular exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 8 week exercise training program - consisting of weight training and cardiovascular exercise
Study: NCT06212271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: See arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description.
Study: NCT04939246

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic ablative body radiation therapy
Description: Single-fraction of stereotactic ablative body radiation (SABR) therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian Linac). The prescription dose is dependent on the anatomic location of the lesion and based on previously published safety data.
Study: NCT06464848

Intervention type: OTHER
Intervention: Narrative identity task
Description: All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).

Intervention type: OTHER
Intervention: Narrative identity task
Description: All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).

Intervention type: OTHER
Intervention: Narrative identity task
Description: All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).
Study: NCT06060990

Intervention type: OTHER
Group type: OTHER
Intervention: trace elements
Description: trace elements as biomarkers for response to systemic therapy in metastatic BTCs
Study: NCT06564948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU patients will be identified using targeted limited chart review methods used in our prior studies, scraping clinical notes in the EHR for criminal justice involvement. Initial Identification terms, police, arrest, court, summons, jail, and crime will be used to identify candidates for police involvement, downloading the sentence in which the keyword appeared and the sentence before and after. Next, an iterative process of editing of the search terms will be conducted to remove patients with negation of the keyword (did not commit a crime), and other sentence characteristics that generate false positives (cardiac arrest). Samples of the resulting dataset will be taken, accuracy assessed by examining the surrounding sentences, leading to further iterations and repetition of the process until a high level of accuracy is achieved.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family and Social Justice
Description: Documentation and follow-up by the Cambridge Police Department (CPD) for all mental health-related police calls, including involuntary and voluntary Emergency Department admissions; Established partnerships with city departments, healthcare systems, clergy, courts, businesses, and mental health advocates to ensure timely engagement in mental health treatment and community-based services; Required 40 hours of officer crisis intervention training (CIT), and additional sessions on trauma- informed policing, mental health, procedural justice, race, and crisis negotiation; and Staffing of sworn and civilian staff including specially-trained officers designated to work with individuals living with mental illness, homelessness, and substance abuse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family and Social Justice Service and Navigator (FSJS+Navigator) Intervention
Description: The FSJS+Navigator intervention adds an Emergency Department (ED)-based Systems Navigator, a community health worker with lived experience (as family member or patient) with criminal justice and mental health systems, to the FSJS. This navigator will enhance communication between Cambridge Police Department (CPD), Cambridge Health Alliance (CHA), and community agencies by being the needed point person within the healthcare system (the FSJS intervention only has a CPD-based social worker) to maintain communication to improve mental health services and prevent deeper justice involvement. The Navigator engages with the FSJS process in step i) of the above sequence, engaging the patient in the CHA ED and obtaining consent. The Navigator then discusses the case with the presenting CPD officer, and relays critical information about the context of the service call to ED staff. Next, the Navigator will administer the baseline CAT-MH/SS and assess additional needs (employment, housing, food).
Study: NCT06581809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Algosteril
Description: hemostatic dressing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other Dressings: interface, hydrocellular, hydrofiber
Description: Non-haemostatic dressing
Study: NCT05665166

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
Description: Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
Study: NCT06084715

Intervention type: OTHER
Intervention: Nutritional support
Description: The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
Study: NCT05632315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMT
Description: Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)
Study: NCT05537792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Knee/Ankle Prosthesis
Description: The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
Study: NCT04315246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: radiolabeled DPTA-omburtamab
Description: Biological, radiolabeled DPTA-omburtamab
Study: NCT06619210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
Study: NCT05449535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904 Placebo
Description: Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Study: NCT04756583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification system
Description: Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months
Study: NCT05754580

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Brachytherapy
Description: This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereostatic Body Radiation Therapy
Description: ultra-hypofractionation radiation therapy.
Study: NCT06547086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation with Temporal Interference (TES-TI)
Description: TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation with Temporal Interference (TES-TI)
Description: TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
Study: NCT06642155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPONSIBLEPLAY© MTM-Based Intervention
Description: Participants in this group will receive a theory-based intervention using the Multi-theory Model (MTM) of health behavior change. The intervention includes participatory dialogue, behavioral confidence-building, and strategies to modify the physical and social environments. It also incorporates emotional transformation and practice for change. Sessions will be delivered in-person over three weeks, focusing on promoting responsible gambling behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge-Based Intervention
Description: Participants in this group will receive a knowledge-based intervention that provides information on gambling risks and responsible gambling strategies. The intervention consists of lectures and reading materials delivered in-person over three weeks. It focuses on raising awareness of gambling risks but does not include the behavioral change strategies used in the MTM-based intervention.
Study: NCT06642519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Stimulation
Description: Studies will be conducted using ECoG, with a bidirectional interface, both recording (aim/phase 1) and stimulating (aim/phase 2), during real-world gait and FOG in PD patients over the course of 7-days of gait experiments.
Study: NCT06311435

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RNA Biomarker Blood Test
Description: Blood will be collected into a PaxGene Blood tube for processing by sponsor
Study: NCT06181357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic lung volume reduction in 2 stages
Description: After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endoscopic lung volume reduction in 1 stage
Description: After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure
Study: NCT05399017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZVent
Description: EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
Study: NCT05225675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Intravenous administration of ARGX-117

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of placebo
Study: NCT06260943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target Navigation Pilot Program
Description: Participants will meet with a navigator, in either English, Spanish or Creole, biweekly, in person or virtually, until the first treatment appointment and every three months after. Each session will last approximately one hour; depending on the needs identified, patients will be connected to appropriate institutional or community-based resources.
Study: NCT06439589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2398
Description: HRS2398: Tablets, 40mg/tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion